Use of sodium iodide symporter expression in differentiated thyroid carcinomas

Clinical Endocrinology

Volumn 75, Issue 2, 2011, Pages 247-254

  Morari, Elaine C ^a   Marcello, Marjory A ^a   Guilhen, Ana Carolina T ^a   Cunha, Lucas L ^a   Latuff, Paulo ^a   Soares, Fernando A ^b   Vassallo, José ^a   Ward, Laura S ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; IODINE 131; LEVOTHYROXINE; MESSENGER RNA; MUTANT PROTEIN; RADIOACTIVE IODINE; SODIUM IODIDE SYMPORTER;

ADOLESCENT; ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; BASOLATERAL MEMBRANE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DISEASE ASSOCIATION; FEMALE; FOLLICULAR ADENOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TISSUE MICROARRAY; WILD TYPE;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK; RNA, MESSENGER; SYMPORTERS; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 79960173870     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04032.x     Document Type: Article

References (35)

1. Ward, L.S., &, Graf, H., (2008) Thyroid cancer: increased occurrence of the disease or simply in its detection? Arquivos Brasileiros de Endocrinologia e Metabologia, 52, 1515-1516.
2. Morris, L.G., &, Myssiorek, D., (2010) Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. American Journal of Surgery, 200, 454-461.
3. Sipos, J.A., &, Mazzaferri, E.L., (2010) Thyroid cancer epidemiology and prognostic variables. Clinical Oncology (Royal College of Radiologists (Great Britain)), 22, 395-404.
4. Elisei, R., Molinaro, E., Agate, L., et al. (2010) Are the Clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question The Journal of Clinical Endocrinology and Metabolism, 95, 1516-1527.
5. Eustatia-Rutten, C.F., Corssmit, E.P., Biermasz, N.R., et al. (2006) Survival and death causes in differentiated thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism, 91, 313-319. (Pubitemid 43069155)
6. Dohan, O., &, Carrasco, N., (2003) Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond. Molecular and Cellular Endocrinology, 213, 59-70. (Pubitemid 38229155)
7. Mazzaferri, E.L., &, Jhiang, S.M., (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. The American Journal of Medicine, 97, 418-428. (Pubitemid 24345593)
8. Pacini, F., Agate, L., Elisei, R., et al. (2001) Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. The Journal of Clinical Endocrinology and Metabolism, 86, 4092-4097. (Pubitemid 32848518)
9. Ito, Y., &, Miyauchi, A., (2009) Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocrine Journal, 56, 177-192.
10. Ward, L.S., Santarosa, P.L., Granja, F., et al. (2003) Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Letters, 200, 85-91. (Pubitemid 37222362)
11. Sodre, A.K., Rubio, I.G., Galrao, A.L., et al. (2008) Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining. The Journal of Clinical Endocrinology and Metabolism, 93, 4141-4145.
12. Dai, G., Levy, O., &, Carrasco, N., (1996) Cloning and characterization of the thyroid iodide transporter. Nature, 379, 458-460. (Pubitemid 26039527)
13. Min, J.J., Chung, J.K., Lee, Y.J., et al. (2001) Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. European Journal of Nuclear Medicine, 28, 639-645. (Pubitemid 33815004)
14. Castro, M.R., Bergert, E.R., Goellner, J.R., et al. (2001) Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. The Journal of Clinical Endocrinology and Metabolism, 86, 5627-5632. (Pubitemid 33070298)
15. Lee, S.J., Choi, K.C., Han, J.P., et al. (2007) Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas. Journal of Endocrinological Investigation, 30, 28-34. (Pubitemid 46470380)
16. Peyrottes, I., Navarro, V., Ondo-Mendez, A., et al. (2009) Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. European Journal of Endocrinology, 160, 215-225.
17. Cooper, D.S., Doherty, G.M., Haugen, B.R., et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167-1214.
18. Riesco-Eizaguirre, G., Rodriguez, I., De la Vieja, A., et al. (2009) The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Research, 69, 8317-8325.
19. Castro, M.R., Bergert, E.R., Beito, T.G., et al. (1999) Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. The Journal of Endocrinology, 163, 495-504. (Pubitemid 30033745)
20. Caillou, B., Troalen, F., Baudin, E., et al. (1998) Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. The Journal of Clinical Endocrinology and Metabolism, 83, 4102-4106. (Pubitemid 28513603)
21. Faggiano, A., Caillou, B., Lacroix, L., et al. (2007) Functional characterization of human thyroid tissue with immunohistochemistry. Thyroid, 17, 203-211. (Pubitemid 46557367)
22. Romei, C., Ciampi, R., Faviana, P., et al. (2008) BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocrine-Related Cancer, 15, 511-520. (Pubitemid 351880839)
23. Riesco-Eizaguirre, G., Gutierrez-Martinez, P., Garcia-Cabezas, M.A., et al. (2006) The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocrine-Related Cancer 13, 257-269.
24. Espadinha, C., Santos, J.R., Sobrinho, L.G., et al. (2009) Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency. Clinical Endocrinology (Oxford), 70, 629-635.
25. Brierley, J., Tsang, R., Panzarella, T., et al. (2005) Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clinical Endocrinology (Oxford), 63, 418-427. (Pubitemid 41442336)
26. Sawka, A.M., Brierley, J.D., Tsang, R.W., et al. (2008) An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinology and Metabolism Clinics of North America, 37, 457-480. (Pubitemid 351711675)
27. Kebebew, E., Peng, M., Reiff, E., et al. (2006) Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer, 106, 2592-2597.
28. Kato, M.A., &, Fahey, T.J. 3rd, (2009) Molecular markers in thyroid cancer diagnostics. Surgical Clinics of North America, 89, 1139-1155.
29. Jarzab, B., Wiench, M., Fujarewicz, K., et al. (2005) Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Research, 65, 1587-1597. (Pubitemid 40270189)
30. Fujarewicz, K., Jarzab, M., Eszlinger, M., et al. (2007) A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocrine-Related Cancer, 14, 809-826. (Pubitemid 350074069)
31. Trouttet-Masson, S., Selmi-Ruby, S., Bernier-Valentin, F., et al. (2004) Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. The American Journal of Pathology, 165, 25-34. (Pubitemid 38821811)
32. Neumann, S., Schuchardt, K., Reske, A., et al. (2004) Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules. Thyroid, 14, 99-111. (Pubitemid 38375496)
33. Dohan, O., Baloch, Z., Banrevi, Z., et al. (2001) Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. The Journal of Clinical Endocrinology and Metabolism, 86, 2697-2700. (Pubitemid 32545725)
34. Wapnir, I.L., van de Rijn, M., Nowels, K., et al. (2003) Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. The Journal of Clinical Endocrinology and Metabolism, 88, 1880-1888. (Pubitemid 36623418)
35. Tonacchera, M., Viacava, P., Agretti, P., et al. (2002) Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein. The Journal of Clinical Endocrinology and Metabolism, 87, 352-357. (Pubitemid 34084714)